A Study to Evaluate the Pharmacokinetics and Safety of YHD1119 in Subjects With Renal Impairment and Healthy Subjects

Exclusion Criteria

• •AST or ALT \> 1.5 \* Upper normal range
• •Total bilirubin \> 1.5 \* Upper normal range
• •Blood CPK \> 1.5 \* Upper normal range
• •Total Cholesterol \>1.5 \* Upper normal range
• •Woman who is pregnant or lactating
• •Patients who are difficult to participate in cinical trials judged by Investigators
• •have participated in other clinical trials within 180 days before IP intake